Diabetes Care:T2DM视网膜病变筛查或可2年一次

2012-05-24 樵苏 中国医学论坛报

  英国学者采用模拟模型发现,对于未并发视网膜病变的2型糖尿病患者,每两年而不是每年一次视网膜病变筛查,既安全且经济。该模型预测,两年一次筛查既不增加视力下降风险,又使筛查成本减少25%。研究5月7日在线发表于《糖尿病护理》(Diabetes Care)杂志。    

  英国学者采用模拟模型发现,对于未并发视网膜病变的2型糖尿病患者,每两年而不是每年一次视网膜病变筛查,既安全且经济。该模型预测,两年一次筛查既不增加视力下降风险,又使筛查成本减少25%。研究5月7日在线发表于《糖尿病护理》(Diabetes Care)杂志。



    

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1636505, encodeId=e4e0163650548, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 15 07:58:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900952, encodeId=4174190095207, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Apr 10 17:58:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759142, encodeId=6b911e59142b0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 11:58:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269769, encodeId=da8b1269e6921, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413852, encodeId=8922141385233, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1636505, encodeId=e4e0163650548, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 15 07:58:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900952, encodeId=4174190095207, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Apr 10 17:58:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759142, encodeId=6b911e59142b0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 11:58:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269769, encodeId=da8b1269e6921, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413852, encodeId=8922141385233, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1636505, encodeId=e4e0163650548, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 15 07:58:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900952, encodeId=4174190095207, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Apr 10 17:58:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759142, encodeId=6b911e59142b0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 11:58:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269769, encodeId=da8b1269e6921, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413852, encodeId=8922141385233, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1636505, encodeId=e4e0163650548, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 15 07:58:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900952, encodeId=4174190095207, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Apr 10 17:58:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759142, encodeId=6b911e59142b0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 11:58:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269769, encodeId=da8b1269e6921, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413852, encodeId=8922141385233, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]
    2012-05-26 zutt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1636505, encodeId=e4e0163650548, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Jan 15 07:58:00 CST 2013, time=2013-01-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1900952, encodeId=4174190095207, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Wed Apr 10 17:58:00 CST 2013, time=2013-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1759142, encodeId=6b911e59142b0, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Dec 13 11:58:00 CST 2012, time=2012-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269769, encodeId=da8b1269e6921, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413852, encodeId=8922141385233, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Sat May 26 08:58:00 CST 2012, time=2012-05-26, status=1, ipAttribution=)]

相关资讯

AIM:ACP新指南强调T2DM药物治疗

 近日,美国医师学会(ACP)发布了2型糖尿病(T2DM)口服药治疗临床实践指南。指南强调,二甲双胍应当是大部分生活方式调整无效的2型糖尿病患者的初始治疗药物,并且可在需要时加用第二种药物。该指南2012年2月6日在线发表于《内科学年鉴》(Ann Intern Med. 2012;156:218-231)杂志。   该指南回顾分析了自1966年至2010年在Medl

Diabetes Care:T2DM治疗步入“患者为中心”模式

    美国糖尿病学会(ADA)与欧洲糖尿病研究学会(EASD)联合发布关于2型糖尿病(T2DM)高血糖管理的立场声明,强调以患者为中心的个体化治疗,并提出降糖策略推荐意见(图1)。声明4月19日在线发表于《糖尿病护理》(Diabetes Care)。   T2DM血糖管理日趋复杂,其原因包括数量和种类增多的药物治疗、关于潜在不良反应的问题、关于强化降糖治疗对大血管并发症效